U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H22N4O5
Molecular Weight 398.4133
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CAMOSTAT

SMILES

CN(C)C(=O)COC(=O)Cc1ccc(cc1)OC(=O)c2ccc(cc2)NC(=N)N

InChI

InChIKey=XASIMHXSUQUHLV-UHFFFAOYSA-N
InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23)

HIDE SMILES / InChI

Molecular Formula C20H22N4O5
Molecular Weight 398.4133
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19190233 | https://www.ncbi.nlm.nih.gov/pubmed/3040018

Camostat mesilate (FOY-305) is a synthetic f low-molecular weight protease inhibitor. It is able to inhibit trypsin, prostasin, matriptase and plasma kallikrein. In addition camostat attenuates airway epithelial sodium channel function and enhances mucociliary clearance. Camostat mesilate tablets (FOIPAN®) are approved in Japan and used for the treatment of remission of acute symptoms of chronic pancreatitis and postoperative reflux esophagitis.

CNS Activity

Curator's Comment:: Camostat mesilate (FOY-305) is CNS active in animals. No human data available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2095204
1.0 nM [Ki]
4.0 nM [Ki]
0.576 µM [Ki]
50.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
FOIPAN

Approved Use

INDICATIONS 1. Remission of acute symptoms of chronic pancreatitis 2. Postoperative reflux esophagitis

Launch Date

7.729344E11
Primary
FOIPAN

Approved Use

INDICATIONS 1. Remission of acute symptoms of chronic pancreatitis 2. Postoperative reflux esophagitis

Launch Date

7.729344E11
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
New orally active serine protease inhibitors.
1995 Jul 7
Different effects of oral administration of synthetic trypsin inhibitor on the pancreas between cholecystokinin-A receptor gene knockout mice and wild type mice.
2002 Jul
Circulating ethanol does not stimulate pancreatic secretion in conscious rats.
2003 Nov
[Effects of Chinese herbal medicines on spontaneous chronic pancreatitis in rats and the pathological relationships between formulas and syndromes].
2006 Jul
Strategies of development of antiviral agents directed against influenza virus replication.
2007
[Fibrosis markers in heavy alcohol drinkers].
2007 Aug
Matrix metalloproteinase gene delivery for liver fibrosis.
2008 Feb
Patents

Sample Use Guides

1. Remission of acute symptoms of chronic pancreatitis. The usual dosage for oral use is 600 mg of camostat mesilate daily in three divided doses. The dosage may be adjusted according to the patient’s symptoms. 2. Postoperative reflux esophagitis. The usual dosage for oral use is 300 mg of camostat mesilate daily in three divided doses after each meal.
Route of Administration: Oral
Camostat mesilate (500 uM) inhibited generation of TGF-beta by suppressing plasmin activity and reduced the activity of TGF-beta, which blocked in vitro activation of the rat hepatic stellate cells.
Substance Class Chemical
Created
by admin
on Sat Jun 26 00:22:26 UTC 2021
Edited
by admin
on Sat Jun 26 00:22:26 UTC 2021
Record UNII
0FD207WKDU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CAMOSTAT
INN   MI   WHO-DD  
INN  
Official Name English
CAMOSTAT [WHO-DD]
Common Name English
CAMOSTAT [INN]
Common Name English
CAMOSTAT [MI]
Common Name English
P-GUANIDINOBENZOIC ACID, ESTER WITH (P-HYDROXYPHENYL)ACETIC ACID, ESTER WITH N,N-DIMETHYLGLYCOLAMIDE
Common Name English
Classification Tree Code System Code
WHO-VATC QB02AB04
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
WHO-ATC B02AB04
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
NCI_THESAURUS C783
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
FDA ORPHAN DRUG 338211
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
Code System Code Type Description
MESH
C034532
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
MERCK INDEX
M3000
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY Merck Index
EPA CompTox
59721-28-7
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
DRUG CENTRAL
471
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
CAS
59721-28-7
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
DRUG BANK
DB13729
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
ChEMBL
CHEMBL590799
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
PUBCHEM
2536
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
NCI_THESAURUS
C73213
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
FDA UNII
0FD207WKDU
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
EVMPD
SUB06066MIG
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
INN
5068
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
WIKIPEDIA
CAMOSTAT
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
IUPHAR
6432
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
nother in vitro study showed that Camostat reduces significantly the infection of Calu-3 lung cells by SARS-CoV-2, the virus responsible for COVID-19.[9]
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY